US-based healthcare services provider McKesson has reported a net income of $915m, or $7 per diluted share, for the first quarter of fiscal year 2025 (Q1 2025), a 4% decline compared to $958m, or $7.02 per diluted share, for the respective quarter in fiscal year (FY) 2024.
The company’s net income for Q1 2025 increased by 15% compared to $ 791m, or $ 6.02 per diluted share, for the fourth quarter of the fiscal year 2024 (Q4 2024)
The US drugmaker reported total revenues of $79.28bn for Q1 2025, a 6% rise compared to $74.48bn for the same quarter FY 2024, and a 4% increase compared to $76.35bn for Q4 2024.
McKesson reported total operating expenses of $2.12bn for Q1 2025, a 10% increase compared to $1.92bn for the respective quarter in FY 2024.
The company reported an income before tax of $1.08bn for Q1 2025, a 1% decline compared to $1.09bn for the same period in the previous year.
McKesson said its quarterly results were impacted by reduced contributions from its Prescription Technology Solutions segment and slower growth in its Medical-Surgical business.
McKesson CEO Brian Tyler said: “McKesson delivered Adjusted Earnings per Diluted Share growth of 8% in the first quarter.
“As a result of our first-quarter performance and confidence for the remainder of the year, we are raising our guidance range for fiscal 2025 adjusted earnings per diluted share to $31.75 to $32.55.
“We continue to advance our strategic priorities leveraging our broad capabilities across the enterprise. Strong momentum continues across our US Pharmaceutical segment, particularly within our broad oncology offerings.”
McKesson’s US Pharmaceuticals business reported revenues of $71.71bn for Q1 2025, a 7% rise compared to $67.16bn for the same quarter in FY 2024.
The healthcare company’s Prescription Technology Solutions arm reported revenues of $1.24bn for Q1 2025, which remained unchanged compared to the same period in the previous year.
The US drugmaker’s Medical-Surgical Solutions business reported revenues of $2.63bn for Q1 2025, a 1% increase compared to $2.61bn for the respective quarter in FY 2024.
McKesson’s International operations reported revenues of $3.69bn for Q1 2025, a 6% rise compared to $3.46bn for the same period in the previous year.
Tyler added: “We remain confident in our strategy and ability to deliver on our raised fiscal 2025 guidance and longer-term objectives.”
“We are also pleased that the Board approved a 15% increase to the dividend, marking the eighth consecutive year of a dividend increase.
“The Board also authorised a $4.0 billion increase to the share repurchase program. These actions reflect the strong performance and financial position of the company, and the confidence the Board and Management have in our future growth prospects.”
